Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Recombinant Variant of Ciliary Neurotrophic Factor for Weight Loss in Obese Adults: A Randomized, Dose-Ranging Study

Ettinger, Mark P., Littlejohn, Thomas W., Schwartz, Sherwyn L., Weiss, Stuart R., McIlwain, Harris H., Heymsfield, Steven B., Bray, George A., Roberts, William G., Heyman, Eugene R., Stambler, Nancy, Heshka, Stanley, Vicary, Catherine, Guler, Hans-Peter·2003·JAMA

Abstract

Context: Obese individuals tend to resist the weight-regulating effects of exogenously administered leptin. A genetically engineered recombinant human variant ciliary neurotrophic factor (rhvCNTF) that signals through leptinlike pathways in the hypothalamus has been shown to bypass leptin resistance in animal models of obesity. Objective: To identify a safe and well-tolerated dose of rhvCNTF that causes weight loss in obese adults. Design, Setting, and Patients: Twelve-week, double-blind, randomized, parallel-group, dose-ranging, multicenter clinical trial conducted at 2 university obesity clinics and at 5 independent clinical research clinics from March 2000 to August 2001, and including 173 nondiabetic obese adults, 82.6% of whom were women, with a mean (SD) body mass index of 41.1 (4.1). Interventions: Patients were randomly assigned to receive daily for 12 weeks subcutaneous injections of placebo (n = 32) or 0.3 µg/kg (n = 32), 1.0 µg/kg (n = 38), or 2.0 µg/kg (n = 33) of rhvCNTF. Another group received 1.0 µg/kg for 8 weeks and placebo for 4 weeks (n = 38), but they were not included in the primary analysis. All participants received instructions for a reduced-calorie diet (World Health Organization formula minus 500 kcal/d). Main Outcome Measures: Change in weight during the 12-week double-blind treatment period and proportion of patients who achieved a weight loss of at least 5%. Results: Of the 173 randomized patients, 123 (71%) completed the double-blind dosing period. Mean (SEM) changes in kilograms from baseline body weights were 0.1 (0.6) for placebo and −1.5 (0.6) for the 0.3, −4.1 (0.6) for the 1.0, and –3.4 (0.7) for the 2.0 µg/kg of rhvCNTF dosage groups (P<.001, test for trend). Two patients (8.7%) in the placebo and 2 (8.3%) in the 0.3-µg/kg, 8 (29.6%) in the 1.0-µg/kg, and 5 (26%) in the 2.0-µg/kg treatment groups achieved a weight loss of at least 5%. Recombinant human variant CNTF was generally well tolerated although adverse events occurred in 75% of patients receiving placebo and 78% to 93% of patients receiving rhvCNTF, in a dose-related fashion, with mild injection site reactions as the most frequently reported adverse event. Conclusions: In this initial, dose-ranging, 12-week study, treatment with rhvCNTF resulted in more weight loss than placebo. These preliminary findings require confirmation in large prospective clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.289.14.1826

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 205

Metadata

Authors
Ettinger, M. P., Littlejohn, T. W., Schwartz, S. L., Weiss, S. R., McIlwain, H. H., Heymsfield, S. B., Bray, G. A., Roberts, W. G., Heyman, E. R., Stambler, N., Heshka, S., Vicary, C., & Guler, H.-P.
Venue
JAMA
Published
2003-04-09
Volume
289
Issue
14
Pages
1826
ISSN
0098-7484
OpenAlex
W2153599456
Cited by
205
References
3
FWCI
6.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant Variant of Ciliary Neurotrophic Factor for Weight Loss in Obese Adults: A Randomized, Dose-Ranging Study. https://app.cochat.ai/papers/10.1001/jama.289.14.1826
The paper
Ettinger, M. P., Littlejohn, T. W., Schwartz, S. L., Weiss, S. R., McIlwain, H. H., Heymsfield, S. B., Bray, G. A., Roberts, W. G., Heyman, E. R., Stambler, N., Heshka, S., Vicary, C., & Guler, H.-P. (2003). Recombinant Variant of Ciliary Neurotrophic Factor for Weight Loss in Obese Adults: A Randomized, Dose-Ranging Study. JAMA. https://doi.org/10.1001/jama.289.14.1826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.